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Running title: Function of the TRAF2-cIAP1/2 interacting motif
TNF receptor associated factor-2
(TRAF2) binds to cIAP1 and cIAP2 (cIAP1/2) 
and recruits them to the cytoplasmic domain 
of several members of the TNF receptor 
superfamily (TNFRSF), including the TNF-
TNFR1 ligand-receptor complex. Here we 
define a cIAP1/2 interacting motif (CIM) 
within the TRAF-N domain of TRAF2, and 
use TRAF2 CIM mutants to determine the 
role of TRAF2 and cIAP1/2 individually, and 
the TRAF2-cIAP1/2 interaction, in TNFR1
dependent signaling. We show that both the 
TRAF2 RING domain and the TRAF2 CIM 
are required to regulate NF-B inducing 
kinase (NIK) stability and suppress 
constitutive non-canonical NF-B activation. 
Conversely, following TNFR1 stimulation, 
cells bearing a CIM mutated TRAF2 showed
reduced canonical NF-B activation and TNF 
induced RIPK1 ubiquitylation. Remarkably, 
the RING domain of TRAF2 was dispensable 
for these functions. However, like the TRAF2 
CIM, the RING domain of TRAF2 was 
required for protection against TNF induced 
apoptosis.  These results show that TRAF2 
has anti-apoptotic signaling roles in addition  
to promoting NF-B signaling and that 
efficient activation of NF-B by TNFR1 
requires the recruitment of cIAP1/2 by 
TRAF2.
The inhibitor of apoptosis (IAP) family 
is comprised of baculoviral IAP repeat (BIR) 
containing proteins, of which several also bear a 
RING domain that is capable of acting as a 
ubiquitin E3 ligase (1). cIAP1 and cIAP2 are 
two RING containing IAPs whose amplification 
or genetic mutation has been associated with
cancers, and may promote tumor cell survival 
(2-8). These highly conserved IAPs were 
initially identified as components of a TRAF2 
containing complex bound to the cytoplasmic 
domain of TNFR2 (9), and have subsequently 
been implicated in the regulation of signaling by 
several more receptors of the TNF superfamily 
(TNFSF) (10-21). While the BIR1 domain of 
cIAP1/2 mediates binding to TRAF2 (17,22,23),
the complementary binding region of TRAF2 is 
unknown, and the relative roles of TRAF2 and 
cIAP1/2 E3 ligase activity in TNF superfamily 
(TNFSF) signaling remain unclear. 
Genetic deletion of TRAF2 in the mouse 
results in early post-natal lethality that is caused 
by increased NF-B-mediated TNF production 
and increased cellular sensitivity to TNF killing 
(12,24,25). Most TRAF family members, 
including TRAF2, bear RING E3 ubiquitin 
ligase domains that are believed to catalyze 
K63-linked ubiquitylation (26,27). One of the 
proposed targets of TRAF2 RING E3 ligase 
activity is RIPK1 (28,29), which is modified 
with K63-linked polyubiquitin chains upon 
TNFR1 activation. This modified TNFR1 
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2complexed RIPK1 has been proposed to serve as 
a platform for the recruitment and/or activation 
of TAB2/TAB3/TAK1 and NEMO/IKK/IKK
kinase complexes (30-32), which target the NF-
B inhibitor IB for K48-linked polyubiquitin-
mediated proteasomal degradation, to initiate 
canonical p65-dependent NF-B gene 
transcription. 
As in the case of TRAF2, genetic 
deletion of cIAP1, or IAP antagonist induced 
loss of  cIAP1/2, also sensitizes cells to TNF 
killing (16,19,33-36). Also like TRAF2, both 
cIAP1 and cIAP2 have been reported to 
ubiquitylate RIPK1 (10,15,16). Consistent with 
the idea that cIAP1/2 play an important role in 
the activation of NF-B by TNF, the removal of 
cIAP1/2 limits TNF from inducing NF-B by 
the canonical pathway (10,15,16). While it 
remains possible that both TRAF2 and cIAP1/2 
play similar roles in modulating TNFR1 
signaling through RIPK1 ubiquitylation, it is 
unknown whether cIAP1/2 act indirectly by 
activating the E3 ligase activity of TRAF2, or if 
cIAP1/2 act in combination with TRAF2 to 
directly ubiquitylate RIPK1, or alternatively, 
whether cIAP1/2 are the major E3 ligases for 
RIPK1 and TRAF2's role is to recruit them to 
TNFR1.
Both TRAF2 or cIAP1/2 deletion causes 
constitutive non-canonical NF-B activity, 
which occurs by stabilization of the NF-B
inducing kinase NIK, IKK activation, and 
processing of the non-canonical NF-B subunit 
p100, to the active p52 form. Activation of non-
canonical NF-B can occur by proteasomal or 
lysosomal degradation of cIAP1, TRAF2 or 
TRAF3 and is mediated by ligand induced 
activation of TNFSF receptors such as TNFR2, 
CD40, BAFFR or FN14 (12,13,17,20,21,37-44).
On the basis of these recent studies (11,12,33) it 
appears that TRAF3 binding to NIK recruits the 
TRAF2-cIAP1/2 module and that cIAP1/2 
mediate K48-linked ubiquitylation of NIK, 
which reduces NIK to undetectable levels in 
resting cells and prevents spontaneous non-
canonical NF-B signals.
In this study we have identified 
TRAF2’s cIAP1/2 interaction motif (CIM), and 
used TRAF2 CIM mutants defective in cIAP1/2 
binding to determine how cIAP1/2 and TRAF2 
coordinately suppress non-canonical NF-B
activation and regulate signaling from TNFR1. 
EXPERIMENTAL PROCEDURES
Cell Culture, Transfections, Constructs 
and Lentiviral Infections. All cell lines were 
maintained at 37˚C, 10% CO2 in DMEM 
supplemented with 8% FBS and passaged twice 
weekly. Transient transfections using 1μg DNA 
per 10cm tissue culture plate were performed 
with Effectene™ (Qiagen) using manufacturer’s
protocols. The NF-B lentiviral reporter vector 
pTRH1 mCMV NF-B dscGFP was purchased 
from System Biosciences. Cre-recombinase and
SV40 Large T antigen were cloned into the 
lentiviral vector pFU. Mouse TRAF2 and the 
CIM and RING domain TRAF2 mutants were 
cloned into pEF-NFLAG and the 4-hydroxy 
tamoxifen inducible lentiviral vector pF 5x
UAS, which we have described in detail
elsewhere (19,45). Full length cIAP1 and the 
BIR1 constructs were cloned into pEF-NHA. 
Complete sequence of all constructs can be 
obtained upon request. Lentiviral particles were 
generated as previously described (17,19).
Antibodies. The primary antibodies used 
were anti-FLAG (Sigma: F-3165), anti--actin 
(Sigma: A-1978), anti-RIPK1 (Mouse, BD 
Transduction Laboratories: 610458. Human, 
Pharmingen: 551042), anti-p65 (Santa Cruz: SC-
372 ), anti-phospho-Ser p65 (Cell Signalling: 
#3033), anti-phospho-Ser32/36 IkB (Cell 
Signaling #9246), anti-IkB (Cell Signaling: 
#9242 ), anti-TNFR1 (Abcam: #19139), anti-
TRAF2 (Pharmingen: 558890, Santa Cruz: SC-
876, Calbiochem: AP1040), anti-cIAP1 (Alexis, 
ALX-803-335), anti-cIAP pan (RnD: 
MAB3400), anti-cIAP2 (in house, 16E6-3), anti-
TRADD (Santa Cruz: SC-7868), anti-NIK (Cell 
Signaling: 4994), anti-p100/p52 (Cell Signaling: 
4882).
Generation of MEFs. Knock-out MEFs 
were generated from E15 embryos using 
standard procedures and infected with SV40 
Large T antigen expressing lentivirus. TRAF2 
conditional knock-out MEFs were similarly 
generated from TRAF2 LoxP/LoxP E15 
embryos. To delete TRAF2 the transformed 
MEFs were infected with a cre expressing 
lentivirus (pFU cre SV40 Hygro) and deletion 
was confirmed by PCR and Western blotting. 
Death Assays. Cells were seeded on 12 
well tissue culture plates at approximately 70
percent confluency and allowed to adhere. 
Compound A (500 nM), described in (19),  or 
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3human Fc-TNF (60 ng/ml) were added to cells 
for 24 hrs and cell death measured by Propidium 
Iodide (PI) staining and flow cytometry. In each 
sample 10,000 events were measured, and the 
cell death (% PI positive cells) quantified. 
Western Blotting and 
Immunoprecipitations. Immunoprecipitations 
were performed as previously described
(17,19,46) with some minor alterations. Briefly, 
4x10
7
 MEFs were treated in the presence or 
absence of human FLAG-TNF at 1 g/ml for 5 
minutes. Cells were lysed in IP-lysis buffer (30 
mM Tris-HCl, pH 7.4, 120 mM NaCl, 2 mM 
EDTA, 2 mM KCl, 1 % TX100, Roche complete 
protease-inhibitor cocktail) at 4 °C for 30 
minutes. The lysates were centrifuged at 15,000g
for 30 minutes. 0.5 g of FLAG-TNF was added 
to the non-stimulated (time=0) control and the 
TNF-R1 complex was precipitated using M2 
beads (Sigma) for 16 hours. The beads were 
washed five times with IP-lysis buffer and eluted 
with 2x LDS buffer (NuPAGE, Invitrogen). 
Proteins were separated by SDS-PAGE 
(NuPAGE, Invitrogen) and analyzed by Western 
blotting. Membranes were stripped with 50 mM 
Glycine (pH 2.3) and reprobed with other 
antibodies.
Immunofluorescence. MEFs grown 
overnight on glass coverslips were treated with 
Fc-TNF  (60ng/ml) for the indicated times,
immediately fixed with 3.2% paraformaldehyde 
for 20 minutes, washed in PBS, and 
permeabilized with 0.5% TritonX-100 for 5 
minutes. Cells were blocked, incubated with p65 
antibody, washed four times with PBS, and then 
incubated with anti-rabbit Alexafluor488 
conjugated secondary antibody (Invitrogen) and 
washed four times again. All blocking steps and 
antibody incubations were performed with PBS 
containing 1% BSA for 30 minutes. Cells were 
viewed on a Olympus BX50 fluorescence 
microscope and SPOT RT imaging software 
using a x40 objective. 
RESULTS
Identification of a cIAP1 and cIAP2 
interacting motif (CIM) in TRAF2. The cIAP1 
BIR1 domain and several key residues within 
this region have been shown to mediate cIAP1 
binding to TRAF2 (17,22,23). However, the 
region of TRAF2 required for cIAP1 and cIAP2 
binding has not been clearly defined since yeast 
two hybrid experiments suggested the TRAF-N
domain was important (9). Our own yeast two 
hybrid analysis suggested that a TRAF2-N
domain containing fragment, residues 262-349, 
is sufficient for cIAP1/2 binding (Fig. 1A, 1C
and not shown). To verify the ability of this 
region to bind cIAP1 in vivo, we performed co-
immunoprecipitation experiments in 293T cells. 
Immunoprecipitation of full length FLAG-
TRAF2 confirmed that it interacts with the 
cIAP1 BIR1 domain and can also bind two BIR1 
domain truncation mutants lacking the first 22 
and 39 residues (Fig. 1B) (17,22,23).
Furthermore, a FLAG-TRAF2-N (aa262-349)
construct was sufficient by itself to 
immunoprecipitate HA tagged full length cIAP1 
or the cIAP1 BIR1 domain alone (Fig. 1C).
Experiments using purified cIAP1 BIR1 and 
TRAF2-N domains demonstrated that the 
binding between these two regions was direct 
(Fig. 2D).
While the crystal structure of truncated 
TRAF2 is available, only the C-terminal part of 
the TRAF-N domain is present (47,48) making it 
difficult to identify the potential interaction 
interface between TRAF2-N and cIAP1 BIR1. 
We therefore examined the conservation of the 
TRAF2-N domain from a number of organisms 
to predict which residues might be important for 
the TRAF2-cIAP1 interaction (Fig. 1D). TRAF1 
has also been shown to interact with cIAP1/2 
(9,49) and was also therefore included in the 
alignment. This analysis revealed a cluster of 
residues spanning amino acids 283 to 294 that 
were highly conserved across all TRAF2 species 
examined and also TRAF1 (Fig. 1D). 
Importantly, this region showed little 
conservation with TRAF3 or Drosophila TRAF2 
(Fig. S1A and S1B), none of which bind cIAP 
proteins. We therefore created several alanine 
point substitutions between or near mouse 
TRAF2 residues 283-294, a TRAF2 deletion 
spanning the residues 283-293, and a TRAF2 
truncation by introducing a stop codon at residue 
D310 (Fig. 1D). 
TRAF2 residues 283-293 are required 
for binding to cIAP1 and cIAP2. To determine 
which residues of TRAF2 are important for 
binding cIAP1 and cIAP2 we transiently 
transfected the indicated FLAG-TRAF2 
constructs (Fig. 1D and 2A) into 293T cells and 
examined their binding to endogenous cIAP1 
and over expressed cIAP2 by FLAG 
immunoprecipitation and Western blot. As 
before TRAF2-N (262-349) and wildtype (WT) 
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4TRAF2 bound cIAP1 and, as expected, TRAF1 
also immunoprecipitated cIAP1. The TRAF2 
deletion, 283-293 did not bind detectable 
amounts of cIAP1 or cIAP2, and the double 
alanine point substitution EVE292AVA mutant 
showed drastically reduced binding to both 
cIAP1 and cIAP2 (Fig. 2A-2D). Single alanine 
point substitution of either E292 or E294 was 
less disruptive of cIAP1 and cIAP2 binding than
mutation of both residues in the EVE292AVA
mutant (Fig. 2B). TRAF2 E283A (and 
EN283AA) showed slightly reduced cIAP1 
binding, but the other TRAF2 mutants, including 
the TRAF2 D310 truncation mutant and a 
RING mutant lacking the first 87 amino acids, 
all interacted with cIAP1 like wild type TRAF2 
(Fig. 2A, 2B). Similar decreases in TRAF2 
mutant binding to cIAP1 were also observed in 
other cell types, such as D645 glioma cells (Fig. 
S1C). These mutations are unlikely to affect 
TRAF2 trimerization because the cIAP1/2 
interacting motif was not present in the trimeric 
TRAF2 crystal structure (47,48). Consistent with 
the idea that the TRAF2 mutations do not affect 
TRAF2 structure dramatically, the TRAF2 
mutants with reduced binding to cIAP1/2 
interacted with endogenous TRADD and RIPK1 
to the same extent as the wild type protein (Fig. 
2C) (50). Experiments using purified cIAP1 or 
cIAP2 BIR1 domain proteins with purified wild 
type, EVE292AVA or 283-293 TRAF2-N
domain proteins confirmed that BIR1 binding to 
TRAF2-N was direct and that mutant TRAF2-N
binding was reduced (EVE292AVA) or 
abolished (283-293) (Fig. 2D). The cIAP1/2 
interacting motif (CIM) of TRAF2 therefore 
spans residues 283-294, and mediates the direct 
interaction between the TRAF-N domain of 
TRAF2 and the BIR1 domain of cIAP1.
A functional TRAF2 CIM and RING 
domain are required to inhibit non-canonical 
NF-B. In unstimulated WT cells TRAF3 
binding to NIK recruits a TRAF2-cIAP1/2 
complex to allow cIAP1/2 mediated NIK 
degradation and inhibition of spontaneous non-
canonical NF-B (11,12,33,51). Deletion of 
TRAF2 or cIAP1 therefore results in constitutive 
non-canonical NF-B signaling (Fig. 3A, 
3C)(17,19,52). Complementation of TRAF2 
knockout MEFs with the EVE292AVA TRAF2 
mutant, that is still able to bind low amounts of 
cIAP1/2 (Fig. 2B, 2D), was able to partially 
restore NF-B activity in TRAF2 knockout cells 
to the basal levels observed in WT cells (Fig. 
3B, 3C), while the TRAF2 283-293 CIM 
mutant completely failed to do so, as measured 
by increased NIK levels, p100 processing to p52
and NF-B GFP reporter activity (Fig. 3B, 3C). 
The TRAF2 RING domain mutant also failed to 
reduce TRAF2 knockout NIK levels and p100 
processing (Fig. 3C) despite the fact that it binds 
cIAP1 and cIAP2 (Fig. 2B). This shows that 
cIAP1/2 mediated K48-linked ubiquitylation and 
degradation of NIK relies on TRAF2 as an 
adaptor protein, and that the TRAF2 RING 
domain is also essential for the ability of 
cIAP1/2 to degrade NIK.
The TRAF2 CIM is required for 
resistance to TNF induced cell death. TRAF2 
knockout MEFs immortalized with the SV40 
large T antigen are highly susceptible to cell 
death induced by TNF treatment alone (17) (Fig. 
4A). These TRAF2 knockout cells showed no 
significant difference in their ability to be killed 
by TRAIL and only a slight, potentially 
insignificant, difference in their ability to be 
killed by FasL (Fig. 4A), suggesting TRAF2 
primarily provides protection against TNF 
induced apoptosis. Similarly, SV40 large T 
immortalized wild type (WT) MEFs that have 
been treated with the IAP antagonist Compound 
A to remove cIAP1, cIAP2 are killed by TNF 
treatment within 24 hrs (19) (Fig. 4A). Because 
cIAP1/2 are recruited by TRAF2, these data 
indicate that either cIAP1/2 or TRAF2, or both, 
confer protection against TNF killing but do not
distinguish between these possibilities.
Reintroduction of inducible WT 
TRAF2, or the E283A TRAF2 mutant that is 
able to bind cIAP1/2, into TRAF2 knockout 
MEFs almost fully restored protection against 
TNF killing (Fig. 4B, 4C). However, induction 
of the TRAF2 CIM 283-293, EVE292AVA or 
RING domain mutants in TRAF2 knockout 
MEFs failed to prevent TNF induced cell death 
(Fig. 4C). These data demonstrate that cIAP1/2 
binding to TRAF2 is crucial to prevent apoptosis 
induced by TNF and suggests that any 
interaction cIAP1/2 may have with RIPK1 (14)
is not sufficient for TNF resistance in the 
absence of their binding TRAF2. Significantly, 
these results indicate that the RING domain of 
TRAF2 is also required for TNF resistance (Fig. 
4C), even though this construct retains the 
ability to bind both cIAP1 and cIAP2 (Fig. 1B). 
Therefore both TRAF2 and cIAP1/2 each play 
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5important roles in protecting cells from TNF 
induced death, and they must do so bound to 
each other. 
TNF induced RIPK1 modification is 
dependent on a functional TRAF2-cIAP1/2 
interaction but the TRAF2 RING domain is 
dispensable. Recent work has suggested that 
cIAP1/2 act as the E3 ubiquitin ligases to 
ubiquitylate RIPK1 following TNFR1 activation 
(14-16). However, it has also been proposed that 
the E3 ubiquitin ligase activity of TRAF2 
mediates ubiquitylation of RIPK1 following 
TNFR1 signaling (28,29). Combined deletion of 
TRAF2 and TRAF5 (TRAF2/TRAF5 DKO) 
significantly prevented RIPK1 ubiquitylation in 
response to TNF stimulation and dramatically 
reduced cIAP1/2 binding to TNFR1 (Fig. 5). 
Thus the phenotype of the TRAF2/TRAF5 
knock-out cells is consistent with both models 
and cannot distinguish between either. 
Restoration of WT TRAF2 expression in 
TRAF2/TRAF5 DKO MEFs restored RIPK1 
ubiquitylation and cIAP1/2 recruitment to 
TNFR1, as expected (Fig. 5). However, 
TRAF2/5 DKO cells reconstituted with the 
TRAF2 CIM 283-293 mutant did not recruit 
cIAP1 and did not restore RIPK1 ubiquitylation 
in response to TNF (Fig. 5). Reintroduction of
TRAF2 RING, which is still able to bind cIAPs 
(Fig.2) but lacks E3 ligase acivity, also restored 
RIPK1 ubiquitylation and cIAP1/2 recruitment 
(Fig. 5). These data are consistent with the idea 
that cIAP1/2 are the most important E3 ligases 
for RIPK1, and fit the model whereby if TRAF2 
does not recruit cIAP1/2 then RIPK1 fails to 
undergo TNF induced ubiquitylation and 
associates with FADD and caspase-8 to induce 
cell death. Intriguingly, although TNF induced 
RIPK1 ubiquitylation (Fig. 5), and NF-B
function (see below) are retained upon loss of 
the TRAF2 RING domain, these cells are still 
susceptible to TNF killing (Fig. 4C).
The TRAF2 CIM, but not the TRAF2 
RING domain, is required for efficient TNF 
induced NF-B activation. As previously 
described (24,53), TNF induced NF-B
activation in TRAF2 knockout cells was similar 
to wildtype cells, as determined by NF-B
reporter assays and Western blotting for p65
phosphorylation and IB (Fig. 3A, 6A). 
Interestingly, we consistently observed that 
cIAP1-/- , TRAF2-/- , and TRAF2/TRAF5 DKO 
MEFs that have been immortalised with the 
large SV40T antigen have increased levels of 
basal phosphorylated p65 when compared to WT 
cells (Fig. 6A, 6B) (17,19). However, this does 
not correlate with increased basal nuclear p65 
levels in any of these cell lines (Fig. 6C, 6D, 7D) 
(17).
TRAF2 and TRAF5 are redundant with 
respect to TNF induced activation of NF-B, 
because deletion of both genes is required to 
prevent it (54). To examine the role of the 
TRAF2-cIAP1/2 interaction in TNF induction of 
NF-B we therefore complemented 
TRAF2/TRAF5 double knockout (DKO) MEFs 
with TRAF2 WT, CIM mutant, and RING 
domain deletion constructs. TRAF2/TRAF5 
DKO cells were significantly impaired in TNF 
induced p65 phosphorylation, IB degradation 
and translocation of p65 to the nucleus (Fig. 6B, 
6C), and complementation with WT TRAF2 
restored all these NF-B associated functions 
(Fig. 6B, 6C). While the TRAF2 CIM mutant 
EVE292AVA, that retains weak cIAP1/2 
binding (Fig. 2B, 2D), partially restored TNF 
induced NF-B function (Fig. 6B, 6C) the 
TRAF2 283-293 CIM mutant was unable to 
restore either IB degradation or nuclear 
translocation of p65 in response to TNF (Fig. 
6B, 6C).
It has recently been suggested that TNF 
induced K63-linked ubiquitylation of TRAF2 on 
lysine 31 regulates binding of TAB2/TAB3 to 
TRAF2 and is required for proper TNF induced 
IKK and NF-B activity (55). If this model is
correct then complementation of TRAF2/TRAF5 
DKO cells with a RING TRAF2 mutant, which 
lacks residues 1-87, should fail to restore TNF 
induced NF-B function. However, we observed 
that TRAF2/TRAF5 DKO MEFs complemented 
with RING TRAF2 restored TNF induced p65 
phosphorylation, IB degradation and 
translocation of p65 to the nucleus to a similar 
level as observed when TRAF2/TRAF5 DKO 
MEFs were complemented with WT TRAF2 
(Fig. 6B, 6C). 
Although rapid TNF induced nuclear 
translocation of p65 is mostly lost in 
TRAF2/TRAF5 DKO MEFs when compared to 
WT cells, some p65 nuclear localization could 
be detected after 60 minutes of TNF stimulation 
(Fig. 6D). Because immunoprecipitated TNFR1 
from TRAF2/ TRAF5 DKO cells still bound low 
levels of cIAP1/2  (Fig. 5), we speculated that 
the late nuclear translocation of p65 in 
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6TRAF2/TRAF5 DKO cells observed by 
immunofluorescence could be caused cIAP1/2 
function. Consistent with this idea, when we 
depleted cIAP1/2 from TRAF2/TRAF5 DKO 
cells using the IAP antagonist Compound A 
(19), p65 translocation to the nucleus failed to 
occur, even 60 minutes after TNF stimulation 
(Fig. 6D).
Deletion of TRAF2 results in enhanced 
TNF induced c-FLIP degradation. Previous 
work has demonstrated that in the absence of 
NF-B signaling in TRAF2/TRAF5 DKO or p65 
knockout cells the lack of TNF induced c-FLIPL
expression sensitises to TNFR1 killing (56).
While it has previously been proposed that 
TRAF2 knockout cells are also sensitive to TNF 
due to reduced basal levels of c-FLIPL (57) our 
Western blots suggested that both unstimulated 
TRAF2-/- and TRAF2/TRAF5 DKO MEFs 
contain almost equivalent levels of c-FLIPL
when compared to WT cells (Fig. 7). However, 
when stimulated with TNF, both TRAF2-/- and 
TRAF2/TRAF5 DKO cells displayed a dramatic 
loss of c-FLIPL when compared to WT cells 
(Fig. 7). Hence despite the normal NF-B
activation in TRAF2-/- MEFs, c-FLIPL is still 
efficiently depleted upon TNF stimulation and 
this probably accounts, at least partially, for their 
increased sensitivity to TNFR1 induced death. 
DISCUSSION
Our study identifying and characterizing 
the role of the cIAP1/2 interacting motif of 
TRAF2 reveals that a key role of TRAF2 is in 
the recruitment of cIAP1/2 into signaling 
platforms. One of these is the NIK kinase 
complex that is essential for non-canonical NF-
B activation. TRAF2 is a key molecule in the 
regulation of NIK stability as loss of TRAF2 
results in NIK stabilisation, activation, and 
constitutive non-canonical NF-B signaling 
(17,52,58). Using TRAF2 CIM and RING 
mutants we complemented TRAF2 knockout 
cells and found that restoration of the normal 
low level of NIK and reduction of spontaneous 
NF-B activity required both the TRAF2 CIM 
and RING domain. These findings are consistent 
with recent reports showing that repression of 
non-canonical NF-B activity requires a 
complex of TRAF3, TRAF2 and cIAP1/2, with 
each component performing a distinct function 
(11,12,19,33). TRAF3 interacts with NIK and 
also binds the TRAF2-cIAP1/2 module, thereby 
bringing cIAP1/2 into the proximity of NIK, 
resulting in cIAP1/2 mediated K48-linked 
ubiquitylation of NIK and its proteasomal 
degradation (11,12,33). These studies and our 
work here demonstrate that in addition to 
cIAP1/2, both the TRAF2 and TRAF3 RING 
domains are required for NIK degradation.
Our data also shows that TNF induced 
nuclear translocation of the canonical NF-B
subunit p65 is significantly delayed in 
TRAF2/TRAF5 DKO cells, which agrees with 
previously reported NF-B electrophoretic 
mobility gel shift assays and in vitro IKK 
activity assays performed on TRAF2/TRAF5 
DKO cells (54,55). cIAP1/2 have also been 
implicated in canonical NF-B signaling 
following TNFR1 activation, and both cIAP1/2 
and TRAF2 have been suggested to be the E3 
ligases required for ubiquitylation of RIPK1 
(10,14-16,28,29). Ubiquitylated RIPK1 is 
believed to be the key signaling platform 
required for correct TNFR1 induced NF-B and 
a TRAF2 CIM mutant was unable to restore 
either RIPK1 ubiquitylation or normal NF-B
signaling in response to TNF. Recently however 
we have shown that RIPK1 knockout MEFs are 
able to induce NF-B in response to TNF  (L.W. 
and J.S, submitted). We therefore believe that 
RIPK1 ubiquitylation serves as a marker for 
TNF induced activation of NF-B but is not a 
requirement. While our work here and recent 
studies therefore suggest a role for cIAP1/2 in 
normal canonical NF-B responses initiated by 
TNF stimulation (10,15,16), it remains unclear 
what their key targets might be given that RIPK1 
itself is dispensable for TNF induced NF-B. 
The ubiquitylation of RIPK1 by cIAP1/2 
has been shown to prevent it associating with 
FADD and caspase-8, thereby limiting TNFR1 
induced cell death (10,15,16). Consistent with 
this model, cIAP1 knockout MEFs have 
increased RIPK1 recruitment to TNFR1 and 
increased sensitivity to TNF killing compared to 
wild type MEFs (10,19). Similarly, IAP 
antagonist treatment that depletes cIAP1/2 
causes a loss of RIPK1 modification following 
TNF stimulation (10,16). Following TNFR1 
activation we observed increased amounts of 
RIPK1 bound to TNFR1 and decreased RIPK1 
ubiquitylation in TRAF2/TRAF5 DKO cells. 
TRAF2/TRAF5 DKO cells reconstituted with 
either WT TRAF2 or a TRAF2 RING mutant, 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on June 15, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
7but not a TRAF2 CIM mutant, regained RIPK1 
ubiquitylation. These results show that TRAF2 
dependent TNF-induced RIPK1 ubiquitylation 
requires an intact TRAF2-cIAP1/2 interaction. 
Combined with the fact that the TRAF2 RING 
domain was dispensable for RIPK1 
ubiquitylation, our  data support the model that 
cIAP1/2 are the critical E3 ligases required for 
RIPK1 ubiquitylation.
While we show that TRAF2 must recruit 
cIAP1/2 in order to properly activate NF-B,
TRAF2 is not just a passive adaptor, because 
TRAF2’s RING domain is required for 
imparting resistance to induction of apoptosis by 
TNF. Our results with TRAF2
-/-
 cells and those 
reconstituted with a TRAF2 RING mutant, 
demonstrates an apparently normal NF-B
induction combined with sensitivity to TNF 
killing. While decreased cIAP1/2 recruitment 
into the TNFR1 signalling complex in TRAF2-/-
MEFs may lead to less RIPK1 ubiquitylation 
and theoretically promote TNF induced cell 
death, our data shows that TRAF2 RING 
restores cIAP1/2 binding to TNFR1 and RIPK1 
ubiquitylation, yet fails to restore TNF 
resistance. The almost normal canonical NF-B
response on the background of increased non-
canonical NF-B signalling in TRAF2
-/-
 MEFs 
((17) and this work) may render them sensitive 
to TNF but this remains to be tested. 
Alternatively, an enhancement in c-FLIPL
degradation may render TRAF2-/- cells more 
susceptible to TNFR1 induced death. To this 
end, we observed a dramatic decrease in c-FLIPL
levels in TRAF2-/- cells upon TNF stimulation 
which is likely to contribute to their enhanced 
TNF sensitivity. While this data fits current 
models where active caspase-8 has been shown 
efficiently cleave c-FLIPL (59), it remains to be 
determined how c-FLIPL levels are regulated by 
the presence of TRAF2.
Our results here define a TRAF2-
c1AP1/2 interacting motif and provide 
independent support for recent studies with IAP 
antagonist compounds that demonstrate a 
fundamental role for cIAP1/2 in regulating TNF 
signaling. Reconstitution of TRAF2 and 
TRAF2/TRAF5 DKO cells with a TRAF2 
RING mutant has however raised new 
questions. This mutant was able to recapitulate 
wild type TRAF2's ability to activate canonical 
NF-B in response to TNF in TRAF2/TRAF5 
DKO cells but was unable to protect TRAF2 
knock-out cells from the cytotoxic activity of 
TNF. It will therefore be interesting to determine 
what the additional cytoprotective function of 
TRAF2 is.
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FIGURE LEGENDS
Figure 1. Identification of a TRAF2-cIAP1/2 Interacting Motif (CIM). A, Schematic of TRAF2 
domain structure and localization of the CIM. B, and C, The TRAF-N domain of TRAF2 interacts
with the BIR1 domain of cIAP1. 293T cells were co-transfected with the indicated HA-cIAP1 
constructs and FLAG-TRAF2 (B) or FLAG-TRAF2-N (C) and their interaction examined by FLAG-
immunoprecipitation and Western blot. M22 and M39 refer to BIR1 deletion constructs lacking the 
first 22 and 39 residues respectively. D, Conservation within the TRAF2-N domain. The TRAF-N
domain of TRAF2 was aligned from the indicated organisms (accession numbers in brackets) and 
compared with the same region of human TRAF1 (bottom line). Identical residues are shaded in black 
and conserved residues in grey. Residues mutated in TRAF2 to examine the effect on cIAP1/2 
binding are highlighted with an asterix and the deletion (283-293) and truncation mutants (D310-stop) 
also indicated.
Figure 2. TRAF2 residues 292EVE294 and 283-293 are important for cIAP1 and cIAP2 binding 
to TRAF2. A, Determination of TRAF2 residues required for cIAP1 binding. 293T cells were 
transfected with the indicated FLAG-TRAF2 constructs for 48 hrs and then immunoprecipitated from 
cell lysates. Binding of endogenous cIAP1 to FLAG-TRAF2 was determined by Western blot. The 
asterix indicates IgG light chain cross reactivity. B, Mutation of both TRAF2 E292 and E294 is
required to reduce cIAP1 and cIAP2 binding. 293T cells were transfected with the indicated FLAG-
TRAF2 constructs in addition to cIAP2. FLAG-TRAF2 complexes were immunoprecipitated and 
TRAF2 binding to endogenous cIAP1 and ectopically expressed cIAP2 determined by Western blot. 
Asterix indicates a non-specific band. C, FLAG-TRAF2 CIM mutants showing reduced cIAP1/2 
binding interact with RIPK1 and TRADD. 293T cells were transfected with FLAG-TRAF2 constructs 
and immunoprecipitated as in (A) and binding to RIPK1 and TRADD determined by Western blot. D,
The TRAF2-N domain binds directly to the cIAP1 BIR1 domain. The indicated GST proteins were 
incubated with purified WT or mutant TRAF2-N domain protein as indicated and, following GST 
immunoprecipitation, binding of the TRAF2-N domain (T2N) detected by Coomassie staining.
Figure 3. The TRAF2 CIM region 283-293 and RING domain are important for repression of 
constitutive non-canonical NF-B activity caused by TRAF2 deletion. A, TRAF2 deletion results 
in constitutive NF-B activity that is further enhanced by TNF stimulation. TRAF2 was deleted from 
parental TRAF2
LoxP/LoxP
 conditional knockout MEFs containing a lentiviral NF-B GFP reporter by 
infection with a lentivirus harboring a Cre recombinase expressing plasmid. TRAF2 parental WT and 
knockout NF-B GFP reporter cells were stimulated with TNF for 24 hrs and reporter activity 
measured by flow cytometry. Blue colouring: WT unstimulated cells. Red colouring: TRAF2
-/-
unstimulated cells. Green colouring: TNF stimulated cells. B, WT but not CIM mutated TRAF2 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on June 15, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
12
restores basal NF-B GFP reporter activity in TRAF2
-/-
 cells. TRAF2 expression in the TRAF2 
conditional knockout MEFs described in (A) was restored with the indicated WT and mutant 
constructs. Basal NF-B reporter activity was measured by flow cytometry 72 hrs post-restoration of 
TRAF2 expression. Yellow colouring: Parental WT MEFs. Light blue colouring: TRAF2
-/-
MEFs. 
Red colouring: Uninduced TRAF2
-/-
 cells reconstituted with the indicated inducible constructs. Blue 
colouring: Induced TRAF2
-/-
 cells reconstituted with the indicated inducible constructs. The 
experiments shown are representative of results obtained on three independent occasions. C, TRAF2 
deletion results in constitutive non-canonical NF-B activity that is not reduced to normal levels by 
expression of TRAF2 CIM 283-293 or RING domain mutants. TRAF2
-/-
 cells described in (A) were 
infected with the indicated inducible lentiviral TRAF2 constructs and TRAF2 expression induced in 
independent clones. 72 hrs post-induction, cells were harvested and analyzed by Western blot for the 
indicated proteins.
Figure 4. TRAF2 CIM residues 292EVE294 and 283-293 are required for TRAF2 mediated 
protection against TNF induced death. A, Immortalized TRAF2
-/-
cells are sensitized to TNF but 
not FasL or TRAIL induced apoptosis. SV40 large T immortalized TRAF2 conditional knockout 
MEFs were infected with Cre recombinase to delete TRAF2. Parental TRAF2
LoxP/LoxP
 and TRAF2
-/-
MEFs were treated with TNF (60 ng/ml), FasL (10 ng/ml), TRAIL (1 μg/ml) or Compound A (500 
nM) as indicated for 24 hrs and cells death quantified by PI staining and flow cytometry. Error bars 
are SEM of at least three independent experiments. B, Restoration of TRAF2 expression in TRAF2
-/-
cells restores TNF resistance. TRAF2
-/-
 MEFs were infected with a lentiviral construct containing 
4HT inducible WT murine TRAF2. TRAF2 expression was induced by the indicated doses of 4HT 
(Western blot, bottom) and cell resistance to TNF  (60 ng/ml) killing after 24 hrs assessed by PI 
staining and flow cytometry. C, TRAF2 292EVE294 and 283-293 mutants do not protect against 
TNF killing in TRAF2
-/-
 MEFs. TRAF2
-/-
 cells were infected with the indicated 4HT inducible 
lentiviral TRAF2 constructs and TRAF2 expression induced for 48 hrs (see Fig. 3C for TRAF2 
expression levels). Cells were then treated with TNF  (60 ng/ml) for a further 24 hrs and cell death 
compared to their uninduced counterparts by PI staining and flow cytometry. Error bars are SEM of 
3-5 independent experiments for several different clones.
Figure 5. The TRAF2 CIM is important for TNF induced RIPK1 ubiquitylation but the TRAF2 
RING domain is dispensable. The indicated MEFs were stimulated with FLAG-TNF (1 μg/ml) for 5 
minutes and the TNFR1 signaling complex precipitated with anti-FLAG antibody as described in the 
Experimental Procedures. The eluted TNFR1 protein complex was examined by Western blot for the 
indicated proteins. To precipitate unstimulated TNFR1 (time=0) FLAG-TNF was added to cell 
lysates. 
Figure 6. The TRAF2 CIM is important for efficient TNF induced NF-B activation but the 
TRAF2 RING domain is dispensable. A, TNF induction of NF-B in TRAF2 knockout MEFs. WT 
and TRAF2
-/-
 cells were treated with TNF  (60 ng/ml) for the indicated times and cell lysates analyzed 
by Western blot. B, Restoration of the normal NF-B response to TNF in TRAF2/TRAF5 double 
knockout MEFs requires the TRAF2 CIM but not the TRAF2 RING domain. The indicated cell types 
were treated with TNF (60 ng/ml) for the time periods shown and cell lysates analyzed by Western 
blot. C, TNF induced translocation of p65 into the nucleus requires the TRAF2 CIM but not the 
TRAF2 RING domain. The indicated MEF cell lines were stimulated with TNF (60 ng/ml) for 20 min 
and p65 localization analyzed by immunostaining and fluorescence microscopy. DKO: 
TRAF2/TRAF5 double knockout. D, Delayed p65 nuclear translocation in TRAF2/TRAF5 DKO
MEFs is prevented by IAP antagonist depletion of cIAP1/2. WT and TRAF2/TRAF5 DKO MEFs 
were treated with 60ng/mL of TNF for the indicated times with or without the IAP antagonist, 
compound A, and p65 localisation examined by immunofluoresence microscopy. 
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Figure 7. Deletion of TRAF2 increases c-FLIPL loss upon TNF stimulation. The indicated MEF 
cell lines were stimulated with TNF for 0, 1 or 2 hours and cell lysates examined by Western blot for 
the proteins shown.
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on June 15, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
Figure 1
D
A
B C
Monkey (XP_001092078)
Mouse (NP_033448)
Rat (NP_001101285)
Dog (XP_857289)
Horse (XP_001497958)
Human Traf1 (NP_005649.1)
Goldfish (CAC92653)
Trout (NP_001117865)
Human (NP_0066961.2)
286
Monkey (XP_001092078)
Mouse (NP_033448)
Rat (NP_001101285)
Dog (XP_857289)
Horse (XP_001497958)
Human Traf1 (NP_005649.1)
Goldfish (CAC92653)
Trout (NP_001117865)
Human (NP_0066961.2)
295
261
257
308
261
261
261
179
264
383
374
349
349
349
345
349
396
336
345
311
311
311
307
311
358
226
* * * * * * * * *
st
op283-293 deletion
    CIM
aa283-294
RING 5xZn Fingers TRAF-N TRAF-C
25 250 272 355 50110097 356
H
A
-B
IR
1 
C1
H
A
-m
22
 B
IR
1 
C1
H
A
-m
39
 B
IR
1 
C1
WB: -FLAG
Lysates:
-FLAG
13
18
41
70
54
35
41
H
A
-m
22
 B
IR
1 
C1
H
A
-m
39
 B
IR
1 
C1
WB: -FLAG
Lysates:
-FLAG
BIR1/m22 BIR1
full length
cIAP1
m39 BIR1
H
A
-C
1
H
A
-B
IR
1 
C1
41
70
54
13
35
25
18
81
18
13
13
18
IP: FLAG-TRAF2
WB:-HA
IP: FLAG-
TRAF2-N (262-349)
WB:-HA
14
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on June 15, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
TR
A
F2
 m
ut
an
ts
A B Fig
ur
e 2
C D
36 29 20 14
GST-cIAP1 BIR1
GST-cIAP2 BIR1
GST-XIAP BIR1
TRAF2N WT
+
TR
A
F2
N
 W
T
+
TR
A
F2
N

28
3
GST-cIAP1 BIR1
GST-cIAP2 BIR1
GST-XIAP BIR1
TRAF2N283
GST
GST-cIAP1 BIR1
GST-cIAP2 BIR1
GST-XIAP BIR1
GST
GST-cIAP1 BIR1
GST-cIAP2 BIR1
GST-XIAP BIR1
GST
GST-cIAP1 BIR1
GST-cIAP2 BIR1
GST-XIAP BIR1
TRAF2N WT
Traf2N AVA
+
TR
A
F2
N
 W
T
+
TR
A
F2
N
 A
VA
37 102025
W
B
:

-
FL
A
G
W
B
:

-
cI
A
P1
e
n
do
g.
cI
AP
1
W
B
:

-
cI
A
P1
lo
ng
 e
xp
.
W
B
:

-
cI
A
P2
6262 9862 49494949 62
FL
A
G
-T
RA
F2
co
n
st
ru
ct
s
WT
283-293
EVE292AVA
E292A
E294A
E283A
RING
control
WT
283-293
EVE292AVA
E292A
E294A
E283A
RING
control
cI
AP
2 
fu
ll
e
n
do
g.
cI
AP
1
*
cI
AP
2
br
ea
kd
ow
n
FL
A
G
-T
RA
F2
 IP
Ly
sa
te
s
TR
AF
2

R
in
g
TR
AF
2
EVE292AVA
FL
A
G
-
TR
A
F 
IP
:
W
B
:
cI
A
P1
control
TRAF2-N
TRAF1
WT TRAF2
E276A
283-293
E283A
N284A
EN283AA
C287A
R305A
HR307AA
D310 stop
FL
A
G
-T
RA
F
co
n
st
ru
ct
s
e
n
do
g.
cI
AP
1
TR
AF
2-
N
D
31
0
st
op
*
TR
AF
2
4778 60 35 2460 47 78 18 13
e
n
do
g.
cI
AP
1
FL
A
G
-T
RA
F2
 IP
Ly
sa
te
s
e
n
do
g.
R
IP
1
e
n
do
g.
TR
AD
D
WT
E283A
EVE292AVA
283-293
RING
control
W
B
:

-
cI
A
P1
W
B
:

-
R
IP
1
W
B
:

-
TR
A
D
D
W
B
:

-
FL
A
G
FL
A
G
-T
RA
F2
co
n
st
ru
ct
s 4
9
WT
E283A
EVE292AVA
283-293
RING
control
62 62 6238
FL
A
G
-
TR
A
F 
IP
:
W
B
:
FL
A
G
T2
N
15
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on June 15, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
Fi
gu
re
 3
B
C
A
N
IK
W
B
:

-
N
IK
W
B
:

-
N
F
B
2
W
B
:

-
TR
A
F2
4949
WT #1
283-293 #1
TR
A
F2
In
du
ct
io
n
WT parental
TRAF2-/- #1
TRAF2-/- #2
WT #2
E283A
EVE292AVA
#1
EVE292AVA
#2
283-293 #2
RING
W
B
:

-

-
ac
tin
49
-
+
-
+
-
-
-
-
+
-
+
-
+
-
+
-
+
-
+
TR
A
F2
-/-
 c
om
pl
em
en
te
d 
w
ith
 in
du
ci
bl
e 
TR
AF
2
p1
00
p5
2
TR
AF
2

R
IN
G
6298 9862
TR
A
F2
 In
du
ce
d
TR
A
F2
 U
ni
nd
uc
ed
W
ild
ty
pe
29
2A
VA

28
3-
29
3
W
T
T2
-/-
FL
1-
H
 (N
F-

B)
Total no.  of cells
TRAF2-/- complemented
with inducible TRAF2
Total no.  of cells
FL
1-
H
 (N
F-

B)
FL
1-
H
 (N
F-

B)
TR
A
F2
+/
+
TR
A
F2
-/-
Un
tre
at
ed
+
/+
-
/-+/
+
TN
F
+
/+
-
/-
-
/- TN
F
+
/+ TN
F
16
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on June 15, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
Fi
gu
re
 4
B
A C
2030406070 105080
% PI positive (Dead)
9010
0
TR
A
F2
+/
+
TR
A
F2
-/-
 #
1
TR
A
F2
-/-
 #
2
Co
nt
ro
l
TN
F
TR
A
IL
Fa
sL
Cp
A
Cp
A/
TN
F
W
B
:

-
TR
A
F2
R
eb
lo
t:

-

-
ac
tin
4H
T 
(n
M)
0
5
10
10
0
3849 49
TR
AF
2
TR
AF
2
a
ct
in
2030406070 105080
% PI positive (Dead)
90
20
40
60
80
10
0
12
0
14
0
0n
M
1n
M
10
nM
5n
M
10
0n
M
TR
A
F2
+/
+
TN
F 
(n
g/m
L)
0
T2
-/-
W
ild
ty
pe+
-
-
T2
+/
++
-
+
E2
83
A
+
+
-
-
EV
E2
92
AV
A
-
-
+
+

28
3-
29
3
+
-
-
+
TR
A
F2
-/-
 c
om
pl
em
en
te
d 
w
ith
 in
du
ci
bl
e 
TR
AF
2
+
-
-
+

R
IN
G
TN
F
Ce
ll 
lin
e
% PI positive (Dead)
TR
A
F2
 in
du
ce
d
TR
A
F2
 u
ni
nd
uc
ed
+
-
T2
 in
d.
4H
T
2030406070 1050809010
0
Ce
ll 
lin
e
17
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on June 15, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
Fi
gu
re
5
51 646497 51
TN
F 
(m
in)
W
T
D
K
O
W
T

28
3

R
IN
G
D
K
O
 +
 T
RA
F2
0
5
0
5
0
5
0
5
0
5
W
T
D
K
O
W
T

28
3

R
IN
G
D
K
O
 +
 T
RA
F2
0
5
0
5
0
5
0
5
0
5
IP
 
TN
F 
R
ec
ep
to
r
Ce
ll 
Ly
sa
te
s
W
B
:

-
R
IP
1
W
B
:

-
TR
A
F2
W
B
:

-
cI
A
P1
/2
W
B
:

-
cI
A
P1
/2
lo
ng
.e
xp
.
W
B
:

-
TN
FR
1
W
B
:

-

-
ac
tin
18
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on June 15, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
AD
C
B
TR
AF
2

R
IN
G
TN
F 
(m
in)
W
B
:

-
I
B
W
B
:

-
p6
5P
W
B
:

-
p6
5
R
eb
lo
t

-
TR
A
F2
4962 38 4962 62
T2
 K
O
0
5
15
45
45
T2
/T
5 
DK
O
0
5
15
45
0
5
15
45
W
ild
ty
pe
0
5
15
45
0
5
15
45
0
5
15
45
0
5
15
45

R
IN
G
29
2A
VA

28
3-
29
3
W
ild
ty
pe
T2
/T
5 
DK
O
 c
om
pl
em
en
te
d 
w
ith
 in
du
ci
bl
e 
TR
AF
2
0
5
15W
T
Fi
gu
re
6
49
W
B
:

-
I
B
P
W
B
:

-
I
B
W
B
:

-
p6
5P
W
B
:

-
p6
5
W
B
:

-
TR
A
F2
W
B
:

-

-
ac
tin
4949 49
TN
F 
(m
in)
35
62 62 6238 38 38 38
TR
A
F2
+/
+
TR
A
F2
-/-
0
5
10
20
35
0
5
10
20
m
er
ge
Un
tre
at
ed
p6
5
H
oe
ch
st
m
er
ge
p6
5
H
oe
ch
st
W
T
D
K
O
D
K
O
+W
T
D
K
O
+2
92
A
V
A
D
K
O
+
28
3
D
K
O
+
R
IN
G
W
T
D
K
O
D
K
O
+W
T
D
K
O
+2
92
A
V
A
D
K
O
+
28
3
D
K
O
+
R
IN
G
TN
F 
tr
ea
te
d
W
T
T2
/T
5 
DK
O
Un
tre
at
ed
TN
F
20
m
in
TN
F
60
m
in
TN
F/
Co
m
p.
A
60
m
in
Co
m
p.
 A
60
m
in
p6
5 
st
ai
ni
ng
19
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on June 15, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
Fi
gu
re
7
W
B
:

-
cF
LI
P
W
B
:

-
PA
R
P
W
B
:

-
TR
A
F2
0
1
2
W
T
0
1
2
0
1
2
T2
-/-
T2
/T
5 
DK
O
TN
F
 
(h
rs
)
TR
AF
2
PA
R
P
cl
ea
ve
d
PA
R
P
cF
LI
P-
L
20
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on June 15, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
